购物车
- 全部删除
- 您的购物车当前为空
Patritumab deruxtecan (HER3-DXd)为一抗体-药物偶联物(ADC),其结构为全人源IgG1单克隆抗体Patritumab通过含四肽的裂解性连接子与拓扑异构酶 I 抑制剂药效团相连。
Patritumab deruxtecan (HER3-DXd)为一抗体-药物偶联物(ADC),其结构为全人源IgG1单克隆抗体Patritumab通过含四肽的裂解性连接子与拓扑异构酶 I 抑制剂药效团相连。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 6,225 | 6-8周 | |
5 mg | ¥ 16,240 | 6-8周 | |
10 mg | ¥ 24,360 | 6-8周 |
产品描述 | Patritumab deruxtecan (HER3-DXd), an antibody-drug conjugate (ADC), comprises a fully human anti-HER3 IgG1 monoclonal antibody, Patritumab, linked to a topoisomerase I inhibitor payload through a tetrapeptide-based cleavable linker, demonstrating anticancer activity [1]. |
体外活性 | Patritumab deruxtecan 对表达HER3突变的乳腺癌细胞显示出抗肿瘤活性,这一效果不受HER2表达水平影响[1]。在0-100 nM浓度范围内,Patritumab deruxtecan与包括HER3突变体在内的所有HER3 WT MDA-MB-231细胞表面结合呈现出浓度依赖性,但对HER3^EV细胞则无结合作用[1]。 |
别名 | U3-1287, HER3-DXd |
CAS No. | 2227102-46-5 |
存储 | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容